Pharmaceutical News and Articles
Comprehensive and up-to-date drug news for both consumers and healthcare professionals.
GLP-1 Receptor Agonists Improve Glycemic, Weight Outcomes in Children With T2D
TUESDAY, Sept. 23, 2025 -- In children and adolescents with type 2 diabetes (T2D) or obesity, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) improve...
Kroger and AquaStar Recall 85,000+ Bags of Shrimp Over Radiation Risk
TUESDAY, Sept. 23, 2025 — More than 85,000 bags of frozen shrimp sold under Kroger and AquaStar brands have been recalled because of possible...
Shunt Surgery Beneficial in Idiopathic Normal-Pressure Hydrocephalus
TUESDAY, Sept. 23, 2025 -- Shunt surgery significantly improves gait velocity at three months among patients with idiopathic normal-pressure hydrocephalus with...
Nonatherothrombotic Causes Account for Much of MI Burden in Younger Adults
TUESDAY, Sept. 23, 2025 -- For persons aged 65 years and younger, nonatherothrombotic causes comprise a considerable burden of acute myocardial infarction...
Repetitive Head Impact Exposure Tied to Disruption at Depths of Sulci
TUESDAY, Sept. 23, 2025 -- Higher repetitive head impact (RHI) exposure is associated with microstructural disruption at the depths of sulci, according to a...
Inpatient Hep C Consultation After Delivery Tied to Better Treatment Completion
TUESDAY, Sept. 23, 2025 -- Providing immediate bedside hepatitis C virus (HCV) consultation at discharge from labor and delivery for women with HCV-affected...
Teen Develops Rare Vaginal Cancer Typically Found In Older Women
TUESDAY, Sept. 23, 2025 — Liliana “Lili” Casteneda had what she thought was her first period at the age of 14, during the height of the COVID-19 pandemic.But t...
FDA to Approve New Use of Cancer Drug for Autism Symptoms in Kids
TUESDAY, Sept. 23, 2025 — A decades-old cancer drug may soon be approved to help kids with certain autism-related symptoms linked to folate deficiency.The U...
Trump Links Tylenol, Vaccines to Autism Without Evidence, Experts Say
TUESDAY, Sept. 23, 2025 — President Donald Trump on Monday linked autism to acetaminophen use in pregnancy and vaccines — claims that scientists say are not su...
Costco Recalls Ahi Tuna Poke in 30+ States Over Listeria Risk
TUESDAY, Sept. 23, 2025 — Costco has recalled more than 3,000 pounds of its Kirkland Signature Ahi Tuna Wasabi Poke after testing found a risk of listeria c...
FDA Approves Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) Subcutaneous Injection Formulation of Keytruda for Use in Solid Tumors
RAHWAY, N.J.--(BUSINESS WIRE) September 19, 2025 -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S...
FDA Grants Accelerated Approval to Forzinity (elamipretide hydrochloride) for the Treatment of Barth Syndrome
NEEDHAM, Mass., Sept. 19, 2025 /PRNewswire/ — Stealth BioTherapeutics Inc. (the “Company” or “Stealth”), a commercial-stage...
Incyte Announces Additional FDA Approval of Opzelura (ruxolitinib) Cream in Children Ages 2-11 with Atopic Dermatitis
WILMINGTON, Del.--(BUSINESS WIRE)--Sep. 18, 2025-- Incyte (Nasdaq: INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Opzelura...
FDA Approves Enbumyst (bumetanide) Nasal Spray for the Treatment of Edema Associated with Congestive Heart Failure, Liver Disease and Kidney Disease
HENDERSON, Nev.--(BUSINESS WIRE) September 15, 2025 --Corstasis Therapeutics Inc., an innovative biopharmaceutical company providing enhanced outpatient...
Intercept Announces Voluntary Withdrawal of Ocaliva for Primary Biliary Cholangitis (PBC) from the US Market; FDA Places US Clinical Trials on Hold
September 12, 2025. MORRISTOWN, N.J., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a wholly owned biopharmaceutical subsidiary of...
FDA Files Corcept’s New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Sep. 10, 2025-- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery...
Stealth Biotherapeutics Announces FDA Acceptance of Elamipretide NDA Resubmission
NEEDHAM, Mass., Aug. 21, 2025 /PRNewswire/ — Stealth BioTherapeutics, a clinical-stage biotechnology company focused on the discovery, development and...
PTC Therapeutics Receives Complete Response Letter for Vatiquinone NDA
WARREN, N.J., Aug. 19, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the U.S. Food and Drug Administration (FDA) has issued a...
Stealth Biotherapeutics Resubmits New Drug Application for Elamipretide for the Treatment of Barth Syndrome
NEEDHAM, Mass., Aug. 18, 2025 /PRNewswire/ — Stealth BioTherapeutics, a clinical-stage biotechnology company focused on the discovery, development...
Arvinas Announces FDA Acceptance of the New Drug Application for Vepdegestrant for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer
NEW HAVEN, Conn., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), today with its partner Pfizer Inc. (NYSE: PFE), announced that the U.S. Food...
Ionis Announces Positive Topline Results From Pivotal Study of Zilganersen in Alexander Disease
CARLSBAD, Calif.--(BUSINESS WIRE)--Sep. 22, 2025-- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced positive topline results from the pivotal study...
Johnson & Johnson’s Investigational Seltorexant Shows Numerically Higher Response in Patients with Depression with Insomnia Symptoms, with Fewer Side Effects Compared to Quetiapine XR
TITUSVILLE, NJ. (September 22, 2025) – Johnson & Johnson announced results from the Phase 3 MDD3005 26-week clinical trial evaluating the efficacy...
Positive Phase III Results Show Genentech’s Giredestrant Significantly Improved Progression-Free Survival in ER-Positive Advanced Breast Cancer
South San Francisco, CA -- September 21, 2025 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive results from the...
UCB Announces Successful First-in-Patient Trial for Galvokimig in Moderate-to-Severe Atopic Dermatitis at EADV
Brussels (Belgium), September 18, 2025 – 07:00 (CEST) – UCB, a global biopharmaceutical company, today announced new 12-week efficacy and 18-week...
Regeneron Announces Positive Phase 3 Trial in Adults with Ultra-Rare Genetic Disorder Fibrodysplasia Ossificans Progressiva (FOP), Demonstrating that Garetosmab Prevents Greater than 99% of Abnormal Bone Formation
TARRYTOWN, N.Y., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the primary endpoint was met in the Phase 3...
Browse by news type
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Clinical Trial Results
- Generic Drug Approvals
- Drug Shortages
Drugs.com Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
Disclaimer
This library contains syndicated news articles. These articles have not been peer-reviewed by Drugs.com, and therefore we cannot guarantee accuracy to the highest ethical standards. Do further research as needed. Consultation with your physician is essential.